Journal
PHARMACOGENOMICS
Volume 19, Issue 15, Pages 1217-1229Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2018-0078
Keywords
glioblastoma; next-generation sequencing; personalized medicine; targeted therapy; tumor genomics
Categories
Ask authors/readers for more resources
Glioblastoma has been shown to have many different genetic mutations found both within and between tumor samples. Molecular testing and genomic sequencing has helped to classify diagnoses and clarify difficult to interpret histopathological specimens. Genomic information also plays a critical role in prognostication for patients, with IDHmutations and MGMTmethylation having significant impact of the response to chemotherapy and overall survival of patients. Unfortunately, personalized medicine and targeted therapy against specific mutations have not been shown to improve patient outcomes. As technology continues to improve, exome and RNA sequencing will play a role in the design of clinical trials, classification of patient subgroups and identification of rare mutations that can be targeted by small-molecule inhibitors and biologic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available